Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.38 |
| ▸ | REN | P00797 | 2/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430508 | 0.93 | CACNA1B (0.41) | CACNA1BACECTSBCTSSCTSK | |
| SCHEMBL4294862 | 0.89 | ACE (0.40) | CACNA1BACECTSBCTSSCTSK | |
| SCHEMBL2426240 | 0.83 | KLK5 (0.40) | CACNA1BACECTSBCTSSCTSK | |
| SCHEMBL2430509 | 0.82 | CACNA1B (0.39) | CACNA1BCTSBCTSSCTSKCTSL | |
| SCHEMBL4301232 | 0.78 | NAAA (0.44) | AGTR2 | |
| SCHEMBL8227117 | 0.76 | USP30 (0.43) | ABCB1USP30 | |
| SCHEMBL2744335 | 0.76 | AAK1 (0.40) | CACNA1BACECTSLAAK1 | |
| SCHEMBL6745052 | 0.74 | CMA1 (0.53) | AGTR2CMA1ABCB1 | |
| SCHEMBL4303372 | 0.72 | AGTR2 (0.36) | AGTR2ABCB1 | |
| SCHEMBL2426243 | 0.72 | CTSL (0.38) | CACNA1BACECTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314062-B2 | Macrocyclic compounds as antiviral agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-11-20 | — | — | US | disclosed |
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | CACNA1B 3771/4885ACE 204/4885CTSB 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.